Skip to content
Screener

Nektar Therapeutics NKTR Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Amgen logo
AmgenAMGN
$2.45B+4.7%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.28B+34.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$472K+27.6%
Vera Therapeutics logo
Vera TherapeuticsVERA
$1.86M
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.85M-10.9%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.48B+539%
Enterprise value$2.56B+435%
P/S44.6×+39.4×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.

Filed
May 7, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-212596
Line itemMarch 31, 2026December 31, 2025
Total current liabilities57,70853,536
Operating lease liabilities, less current portion60,63165,256
Liabilities related to the sales of future royalties, net60,27063,157
Other long-term liabilities8,4468,625
Total liabilities187,055190,574
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at March 31, 2026 or December 31, 2025, respectively

Item 1. Condensed Consolidated Financial Statements—Unaudited:

FAQ

What is Nektar Therapeutics's other non-current liabilities?
Nektar Therapeutics (NKTR) reported other non-current liabilities of $8.45M in Q1 2026.
How has Nektar Therapeutics's other non-current liabilities changed year-over-year?
Nektar Therapeutics's other non-current liabilities increased by 25.0% year-over-year, from $6.76M to $8.45M.
What is the long-term trend for Nektar Therapeutics's other non-current liabilities?
Over 5 years (2020 to 2025), Nektar Therapeutics's other non-current liabilities has grown at a -0.8% compound annual growth rate (CAGR), from $8.98M to $8.63M.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about Nektar Therapeutics's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude